Anavex Life Sciences Statistics
Anavex Life Sciences (12X1) Stock Statistics & Valuation Metrics
Total Valuation
Anavex Life Sciences has a market cap or net worth of CHF 72.61M. The enterprise value is CHF 122.28M.
- Market Cap
- CHF 72.61M
- Enterprise Value
- CHF 122.28M
Share Statistics
Anavex Life Sciences has 92,696,840 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 92,696,840
- Owned by Insiders
- 1.66%
- Owned by Institutions
- 32.65%
Financial Efficiency
Anavex Life Sciences’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is -54.19%.
- Return on Equity (ROE)
- -0.49
- Return on Assets (ROA)
- -0.45
- Return on Invested Capital (ROIC)
- -54.19%
- Return on Capital Employed (ROCE)
- -0.54
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.36M
- Employee Count
- 34
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Anavex Life Sciences is -6.35. Anavex Life Sciences’s PEG ratio is -0.05.
- PE Ratio
- -6.35
- PS Ratio
- 0.00
- PB Ratio
- 0.77
- Price to FCF
- -2.57
- Price to Operating Cash Flow
- -2.57
- PEG Ratio
- -0.05
Income Statement
In the last 12 months, Anavex Life Sciences had revenue of 0 and earned -46.38M in profits. Earnings per share was -0.54.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -51.41M
- Pretax Income
- -46.38M
- Net Income
- -46.38M
- EBITDA
- -46.38M
- Earnings Per Share (EPS)
- -0.54
Cash Flow
In the last 12 months, operating cash flow was -33.73M and capital expenditures 0, giving a free cash flow of -33.73M billion.
- Operating Cash Flow
- -33.73M
- Free Cash Flow
- -33.73M
- Free Cash Flow per Share
- -0.36
Dividends & Yields
Anavex Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -38.98%
- Earnings Yield
- -15.05%
Stock Price Statistics
- Beta
- 2.00
- 52-Week Price Change
- ―
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Anavex Life Sciences upcoming earnings date is Nov 30, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Jul 30, 2026
- Next Earnings Date
- Nov 30, 2026
- Ex-Dividend Date
- ―
Financial Position
Anavex Life Sciences as a current ratio of 11.60, with Debt / Equity ratio of 0.00%
- Current Ratio
- 11.60
- Quick Ratio
- 11.60
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 2.21
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Anavex Life Sciences has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Anavex Life Sciences EV to EBITDA ratio is 2.94, with an EV/FCF ratio of 0.94.
- EV to Sales
- 0.00
- EV to EBITDA
- 2.94
- EV to Free Cash Flow
- 0.94
- EV to Operating Cash Flow
- 0.94
Balance Sheet
Anavex Life Sciences has CHF 118.33M in cash and marketable securities with CHF 0.00 in debt, giving a net cash position of CHF 118.33M billion.
- Cash & Marketable Securities
- CHF 118.33M
- Total Debt
- CHF 0.00
- Net Cash
- CHF 118.33M
- Net Cash Per Share
- CHF 1.28
- Tangible Book Value Per Share
- CHF 1.21
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Anavex Life Sciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 73.28%
Scores
- Smart Score
- 1
- AI Score
- ―

